Point72 Asia (Singapore) Pte. Ltd. Protagonist Therapeutics, Inc Transaction History
Point72 Asia (Singapore) Pte. Ltd.
- $480 Billion
- Q2 2024
A detailed history of Point72 Asia (Singapore) Pte. Ltd. transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Point72 Asia (Singapore) Pte. Ltd. holds 14,556 shares of PTGX stock, worth $667,247. This represents 0.11% of its overall portfolio holdings.
Number of Shares
14,556Holding current value
$667,247% of portfolio
0.11%Shares
1 transactions
Others Institutions Holding PTGX
# of Institutions
212Shares Held
59.1MCall Options Held
19KPut Options Held
107K-
Farallon Capital Management LLC San Francisco, CA5.84MShares$268 Million0.98% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$264 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.29MShares$242 Million3.06% of portfolio
-
Bvf Inc San Francisco, CA3.32MShares$152 Million3.52% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.24MShares$149 Million0.0% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $2.25B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...